This study is in progress, not accepting new patients
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Gary Schiller
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Gary Schiller
Professor-in-Residence, Medicine. Authored (or co-authored) 158 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Incyte Corporation
- Links
- Related Info
- ID
- NCT04551066
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 252 people participating
- Last Updated